From profit to impact: lives saved and the future of RSV vaccine development

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	763-765
Number of pages	3
Journal	The Lancet Respiratory Medicine
Volume	11
Issue number	9
DOIs	https://doi.org/10.1016/S2213-2600(23)00301-6
Publication status	Published - Sept 2023

Access to Document

@article{ce7f0d21b1c7412d967f9e968a66d247,

title = "From profit to impact: lives saved and the future of RSV vaccine development",

author = "Natalie Mazur and Yvette L{\"o}wensteyn",

year = "2023",

month = sep,

doi = "10.1016/S2213-2600(23)00301-6",

language = "English",

volume = "11",

pages = "763--765",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - From profit to impact

T2 - lives saved and the future of RSV vaccine development

AU - Mazur, Natalie

AU - Löwensteyn, Yvette

PY - 2023/9

Y1 - 2023/9

UR - https://www.scopus.com/pages/publications/85169004432

U2 - 10.1016/S2213-2600(23)00301-6

DO - 10.1016/S2213-2600(23)00301-6

M3 - Comment/Letter to the editor

C2 - 37657851

AN - SCOPUS:85169004432

SN - 2213-2600

VL - 11

SP - 763

EP - 765

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 9

ER -